Fujifilm Diosynth Biotechnologies is in the middle of a monumental point in the company’s 10-year history, and the CDMO is about to grow even more, as it sets out to be the ‘beating heart’ of the UK’s…
Neurologist and King’s College London professor Christopher Shaw has been researching neurodegenerative diseases like ALS and collaborating with drugmakers for the last 25 years in the hopes of…
Amgen’s blockbuster Otezla just racked up another Phase III win as it looks to continue expanding on its multibillion-dollar revenue stream. The drug hit the primary endpoint in a trial researching…
Thursday marks Novartis’ annual R&D day, and with it comes CEO Vas Narasimhan’s attempt to spotlight the company’s pipeline strategy and emerging stars. The biggest question entering Thursday’s…
After South African scientists reported a new Covid-19 variant — dubbed Omicron by the WHO — scientists became concerned about how effective vaccines and monoclonal antibodies might be against it,…
An inmate in Georgia has been sentenced to seven additional years in prison for running a $3 million fraud scheme to steal and then resell heavy equipment from behind bars — by posing as an AbbVie…
Novartis is plopping down $150 million in cash to pick up an experimental Parkinson’s drug and grab an option to another, a move that puts it on an increasingly popular path in the field’s search for…
A British CDMO and the University of Manchester have teamed up to support the development of low-cost manufacturing of molnupiravir, the antiviral pill for Covid-19 that an FDA adcomm recommended for…
In the rather insular world of biotech, most innovation inevitably comes from a cluster of R&D hubs — Cambridge, San Francisco, etc. But sometimes success stories sprout from rocky soil, which is most…
When GlaxoSmithKline trumpeted its return to neuroscience with a $700 million upfront deal with Alector this summer, it touted its early investments in functional genomics as a key guidepost for that…
